icon-folder.gif   Conference Reports for NATAP  
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
Treatment With Sofosbuvir + Ribavirin for 12 Weeks Achieves SVR12 of 78% in GT 2/3 Interferon-Ineligible, -Intolerant, or -Unwilling Patients: Results of the Phase 3 POSITRON Trial
  Reported by Jules Levin
EASL, April 26 International Liver Congress 2013, Amsterdam
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options - (04/24/13) New England Jnl of Medicine
Ira M. Jacobson1, Eric M. Yoshida2, Mark Sulkowski3, David R. Nelson4, Evguenia Svarovskaia5, Di An5, John McNally5, Diana M. Brainard5, William T. Symonds5, John G. McHutchison5, Stephen Pianko6, Kris V. Kowdley7 1Weill Cornell Medical College, New York, NY, USA; 2University of British Columbia, Vancouver, Canada; 3Johns Hopkins University School of Medicine, Baltimore, MD, USA; 4University of Florida, Gainesville, FL, USA; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Monash Medical Centre and Monash University, Melbourne, Victoria, Australia; 7Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA